Multiple Myeloma Treated With Thalidomide Before Autotransplant or With Conventional Chemotherapy and as Consolidation/Maintenance Treatment in Young and Elderly Patients : 3 Randomized Studies.

PHASE3CompletedINTERVENTIONAL
Timeline

Start Date

May 31, 2003

Study Completion Date

December 31, 2009

Conditions
Multiple Myeloma de Novo Treatment
Interventions
DRUG

Thalidomide, Dexamethasone

Thalidomide 200 mg/d for 3 months, Dexamethasone 40 mg/d D1-D4 and D14-D17 for 28d-3 cycles

DRUG

Vincristin , Adriamycin, Dexamethasone = VAD

Vincristin 0.4 mg/d continUous IV infusion D1-D4, Adriamycin 9 mg/m2 continuous IV infusion D1-D4, Dexamethasone 40 mg/d oral D1-D4 and D15-D18 for 2 first cycles, D1-D4 for the 3d cycle

DRUG

Thalidomide, melphalan, endoxan, dexamethasone (MCDex-Thal)

Thalidomide : 200 mg/d at bedtime for 3 months , melphalan: 6 mg/m2 oral D1-D4, endoxan 600 mg/m2 IV D1, dexamethasone 40 mg/d oral D1-D4 for 28-d 4 cycles

DRUG

melphalan, endoxan, dexamethasone (MCDex)

melphalan: 6 mg/m2 oral D1-D4, endoxan 600 mg/m2 IV D1, dexamethasone 40 mg/d oral D1-D4 for 28-d 4 cycles

DRUG

Thalidomide, Dexamethasone

Thalidomide 200 mg/d on every other 3 months Dexamethasone 40 mg/d D1-D4, D30-D34,D60-D64, D90-D94

Trial Locations (3)

14033

CHU CAEN Dept of Hematology, Caen

75475

CHU Saint Louis Dept of Hematology, Paris

94010

CHU Henri Mondor, Créteil

All Listed Sponsors
collaborator

Laphal

UNKNOWN

lead

University Hospital, Caen

OTHER

NCT01070862 - Multiple Myeloma Treated With Thalidomide Before Autotransplant or With Conventional Chemotherapy and as Consolidation/Maintenance Treatment in Young and Elderly Patients : 3 Randomized Studies. | Biotech Hunter | Biotech Hunter